Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Refixia

- PMLiVE

Novo Nordisk on track to file liraglutide in obesity

Expects regulatory filings in the US and EU by the beginning of 2014

- PMLiVE

Novo Nordisk: Strict US regulation threatens innovation

Warning from CEO Sorensen comes after Tresiba and Ryzodeg fail to win FDA approval

Biogen Idec building

FDA starts review of Biogen Idec’s haemophilia A therapy

Could gain US approval by the first quarter of 2014

- PMLiVE

Interview: Peter Meeus, Novo Nordisk

The managing director of Novo Nordisk UK discusses how education and new partnerships are helping fight the battle against the country’s worsening diabetes crisis

- PMLiVE

Novo Nordisk launches new US insulin campaign

US IndyCar driver, diabetic and FlexPen user Charlie Kimball fronts activities

- PMLiVE

Novo opens doors on new US headquarters

$225m redevelopment for New Jersey life science offices

- PMLiVE

Mixed reaction to Novo Nordisk obesity trial

Analyst says Victoza only has a modest ability to reduce weight in people with diabetes

- PMLiVE

Novo’s Lantus rival Tresiba hits European markets

Company says its insulin degludec is a more flexible alternative to Sanofi's product

- PMLiVE

Building brand strength – Part 4

Commitment, responsiveness and protection – how far will Big Pharma go to preserve its brands?

- PMLiVE

FDA turns down Novo Nordisk’s Tresiba and Ryzodeg

Decision could delay the US launch of the diabetes drugs by two years or more

- PMLiVE

EU nod for Novo Nordisk’s Tresiba and Ryzodeg

Reduced risk of hypoglycaemia may give insulin products edge ahead of Sanofi’s Lantus

- PMLiVE

Novo Nordisk creates all-diabetes pro-cycling team

Team Novo Nordisk includes more than 100 cyclists, triathletes and runners with diabetes

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links